Evidence map›Paper›PMID 9587949›Full record

ArticlePharmaceutical research1998

Drug targeting by polyalkylcyanoacrylate nanoparticles is not efficient against persistent Salmonella.

M E Page-Clisson, H Pinto-Alphandary, E Chachaty, P Couvreur, A Andremont

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

M E Page-ClissonLaboratoire de Pharmacie Galénique et de Biopharmacie, Centre National de la Recherche Scientifique, URA 1218, Université de Paris XI, Châtenay-Malabry, France.
H Pinto-Alphandary
E Chachaty
P Couvreur
A Andremont
Université Paris Cité · FRInstitut Gustave Roussy · FRUniversité Claude Bernard Lyon 1 · FRUniversité Paris-Saclay · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe have investigated the efficacy of colistin and ciprofloxacin, free or bound to polyalkylcyanoacrylate nanoparticles, for the targeting and eradication of Salmonella persisting in the organs of the mononuclear phagocyte system.

methodsA model of persistent S. typhimurium infection was developed in C57BL/6 mice using i.v. inoculation of the plasmid-cured strain C53.

resultsIn vivo and ex vivo experiments showed that the persisting bacteria seem to evolve to a nongrowing state during experimental salmonellosis. In vivo treatment with free or nanoparticle-bound colistin did not significantly reduce the number of viable Salmonella C53, either in the liver or the spleen of infected mice. In contrast, in vivo treatment with ciprofloxacin led to a significant decrease of bacterial counts in the liver whatever the stage of infection and the form used. However, none of the treatments were able to sterilize the spleen or the liver. In ex vivo experiments, colistin was only active against bacteria recovered during the early phase of infection, whereas ciprofloxacin exerted its activity at all times postinfection.

conclusionsWe suggest that the micro-environment in which the bacterial cells persist in vivo probably causes dramatic changes in their susceptibility to antimicrobial agents.

Indexed as

AnimalsAnti-Bacterial AgentsAnti-Infective AgentsCiprofloxacinColistinCyanoacrylatesDrug CarriersFemaleLiverMiceMice, Inbred C57BLMicrobial Sensitivity TestsParticle SizeSalmonella Infections, AnimalSalmonella typhimuriumSpleenAnti-Bacterial AgentsAnti-Infective AgentsCiprofloxacinColistinCyanoacrylatesDrug Carriers

Identifiers

PMID9587949
OpenAlexW1784845355

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.